STAGE IV LUNG CANCER AJCC V8

This early-phase study tests a personalized vaccine made from each patient's unique tumor markers (neo-antigens) to help their immune system fight cancer. It includes up to 25 adults with advanced melanoma, breast cancer, or non-small cell lung cancer that has not responded to st…

This early-phase trial is testing a combination of two drugs, osimertinib and tegavivint, as the first treatment for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC that has spread). The main goal is to find the safest and most effective dose. About 24 adul…

This study tests whether combining three targeted drugs (capmatinib, osimertinib, and ramucirumab) can shrink or stabilize advanced non-small cell lung cancer in people with specific EGFR and MET gene changes. About 66 participants will receive either two or three drugs to see wh…

This phase 3 trial compares a two-drug combination (osimertinib plus bevacizumab) against osimertinib alone as the first treatment for people with advanced EGFR-mutant non-small cell lung cancer. The goal is to see if adding bevacizumab helps control the cancer longer and improve…

This study tests a combination of two drugs—temozolomide (chemotherapy) and atezolizumab (immunotherapy)—for people with small cell lung cancer that has spread or returned after initial treatment. The goal is to see if this combination can shrink tumors and help patients live lon…

This early-phase trial tests whether combining two drugs, carfilzomib and sotorasib, is safe and effective for people with advanced or spreading non-small cell lung cancer that has a specific KRAS G12C mutation. About 15 adults who have already tried a KRAS inhibitor will receive…

This study tests whether adding an experimental drug (SX-682) to a standard immunotherapy (pembrolizumab) helps shrink or control advanced non-small cell lung cancer. About 30 adults with stage IIIC or IV lung cancer that hasn't been treated yet will receive both drugs. The goal …

This study tests two drugs, tepotinib and ramucirumab, for people with advanced non-small cell lung cancer that has a specific genetic change (MET exon 14 skipping). Tepotinib blocks signals that make cancer cells grow, and ramucirumab may stop new blood vessels from feeding the …

This early-stage trial tests the safety and best dose of combining two drugs—vismodegib and atezolizumab—for people with advanced non-small cell lung cancer that has returned or spread. Vismodegib blocks certain enzymes that help cancer grow, while atezolizumab helps the immune s…

This study tests whether combining two targeted drugs—sotorasib and trastuzumab deruxtecan—is safe and effective for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. About 37 adults whose cancer has spread and who have already tried other tr…

This study tests whether adding the anti-inflammatory drug diclofenac can help control tumor growth in people with advanced non-small cell lung cancer whose disease is starting to worsen on immunotherapy alone. About 20 adults will receive diclofenac alongside their current immun…

This early-stage trial tests a new drug (PBF-1129) combined with an immunotherapy (nivolumab) in 30 adults with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand side effects. Participants must have already tr…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps control t…

This study tests if a precise type of proton radiation (pCSI) can help people with breast or lung cancer that has spread to the fluid-filled space around the brain and spinal cord live longer than standard x-ray radiation. About 115 participants will receive either pCSI or standa…

This study tests a type of radiation therapy called craniospinal irradiation for people with breast or lung cancer that has spread to the fluid and lining around the brain and spinal cord. The goal is to see if this treatment can control the cancer in the central nervous system. …

This early-stage study tests a drug called nivolumab, given both through a vein and directly into the fluid around the spine, for people with melanoma or lung cancer that has spread to the lining of the brain (leptomeningeal disease). The goal is to find the safest dose and see i…

This study tests a precise radiation method that treats the entire brain and spinal cord while avoiding the memory center (hippocampus). It is for adults with breast or lung cancer that has spread to the fluid and tissues around the brain and spinal cord. The goal is to see if th…

This study tests a drug called avapritinib in people with advanced solid tumors that have certain genetic changes (CKIT or PDGFRA mutations). The goal is to see if the drug can shrink or control the cancer. About 50 adults with cancers like melanoma, sarcoma, or breast, lung, or …

This study tests whether adding two types of focused radiation (BgRT and SBRT) to the targeted drug osimertinib can better control EGFR-positive non-small cell lung cancer that has started to grow in a few new spots. About 32 adults with advanced lung cancer will receive the comb…

This early-phase trial tests gilteritinib, a drug already approved for leukemia, in 30 people with stage IV ALK-positive non-small cell lung cancer whose cancer has stopped responding to other treatments. The main goals are to find the safest dose and understand side effects. Res…

This study tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can help keep extensive-stage small cell lung cancer under control longer. About 45 adults whose cancer responded to initial chemo-immunotherapy will participa…

This study compares two types of radiation for people with small cell lung cancer that has spread to the brain. One method, stereotactic radiosurgery (SRS), targets tumors precisely with a single high dose. The other, hippocampal-avoidant whole brain radiotherapy (HA-WBRT) plus m…

This study tests whether adding GT103 to the immunotherapy drug pembrolizumab can help people with a specific type of advanced lung cancer (STK11 mutant NSCLC) that has stopped responding to pembrolizumab alone. About 28 adults whose cancer has spread will receive both drugs to s…

This early-stage trial tests a new drug (MRX-2843) combined with a standard treatment (osimertinib) for people with advanced EGFR-mutant non-small cell lung cancer. The goal is to find the safest and most effective dose and to see how well the combination works. About 69 particip…

This study tests a special type of radiation called grid therapy combined with standard immunotherapy for people with stage IV non-small cell lung cancer that has gotten worse after immunotherapy. Grid therapy delivers high doses of radiation to small parts of the tumor, which ma…

This study tests whether adding chemotherapy to immunotherapy (pembrolizumab) helps older adults (70+) with advanced non-small cell lung cancer live longer compared to immunotherapy alone. The trial enrolls 304 participants with stage IIIB-IV cancer and a specific PD-L1 level. Th…

This study tests whether a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy drug (nivolumab) can shrink or slow the growth of advanced LKB1-mutant lung cancer that has stopped responding to standard immunotherapy. About 50 adults with this spe…

This early study tests a combination of two immune-boosting drugs, low-dose IL-2 and pembrolizumab, in 15 people with advanced (stage IV) non-small cell lung cancer who have not had prior treatment. The goal is to see if the combo can reinvigorate tired immune cells to better att…

This study is for people with stage IV or returning non-small cell lung cancer who have already had chemotherapy and immunotherapy. It compares the usual two-drug treatment (docetaxel and ramucirumab) to the same two drugs plus a third drug called cemiplimab. The goal is to see i…

This study tests a special dye that attaches to lung cancer cells and makes them glow under a camera during surgery. The goal is to help surgeons see and remove all cancer, including tiny spots that might otherwise be missed. About 30 adults with lung cancer or lung metastases wi…

This study tests whether a special yoga program can improve physical function, fatigue, sleep, and quality of life for people with lung or esophageal cancer who are getting radiation therapy, as well as for their family caregivers. About 400 patient-caregiver pairs will take part…

This early-phase study tests whether giving palliative radiotherapy together with the drug lurbinectedin is safe for people with extensive-stage small cell lung cancer that has spread beyond the chest. The goal is to relieve symptoms caused by the cancer. About 22 adults whose ca…

This study looks at whether getting immunotherapy in the morning or afternoon makes it work better for people with advanced or spreading solid tumors. The body's internal clock (circadian rhythm) may affect how the immune system responds. Researchers will compare progression-free…

This study tests whether giving radiation in three smaller doses (fractionated stereotactic radiosurgery) is better than the usual single large dose for people whose cancer has spread to the brain. About 269 adults with certain cancers (like lung, breast, or melanoma) will be ran…

This early study tests if a portable device that creates electric fields is safe and practical for people with breast or lung cancer that has spread to the lining of the spine. Only 5 participants will wear the device for at least 28 days. The goal is to see if the treatment is t…

This study tests whether a screening tool can improve how well patients with advanced lung cancer understand their illness. About 100 adults recently diagnosed with stage IV lung cancer will either use the tool or receive usual care. The goal is to help patients make informed dec…

This study looks at how the bacteria in your gut might cause stomach issues like diarrhea and colitis when you take certain cancer drugs called immune checkpoint inhibitors. Researchers will collect stool, blood, and tissue samples from 800 people with melanoma, lung cancer, or g…

This study tracks 800 people with advanced lung, pancreatic, or colorectal cancer to understand why some lose weight and muscle (cachexia) and others don't. By identifying different patterns of weight loss, researchers hope to create better, more personalized treatments in the fu…

This study looks at how T cells change in people with advanced melanoma, lung, or other cancers during anti-PD-1 immunotherapy. Researchers will measure specific markers in blood samples to see if they can predict treatment response or resistance. The goal is to understand why so…

This study looks at how PET/CT scans change during chemoimmunotherapy and radiation for stage IV non-small cell lung cancer. Researchers want to see if these scans can help predict how well the cancer responds to treatment. About 80 adults with advanced lung cancer who haven't ha…

This study looks at how often people with metastatic non-small cell lung cancer have trouble sleeping. Researchers will ask 60 participants to fill out a sleep questionnaire. The goal is to understand how common insomnia is in this group, not to test a treatment.

This study tests a conversation aid that helps lung cancer patients and their doctors share decision-making about treatment. About 100 patients with non-small cell lung cancer will use the tool during appointments, and researchers will measure how involved patients feel and how s…

This study looks at blood and tissue samples from people with advanced non-small cell lung cancer to find markers that predict how well immunotherapy works. The goal is to use these markers to choose the best second-line treatment if the first one stops working. About 535 partici…